title: [Vasoactive intestinal polypeptide prevents injury of pulmonary vascular permeability due to xanthine with xanthine oxidase].
abstract: Hyperpermeability is the crux of pathogenesis of sudden lung edema in many pulmonary disorders, especially in acute lung injury and acute respiratory distress syndrome (ARDS). Using our modified method for assessment of pulmonary vascular permeability, we observed the effects of xanthine with xanthine oxidase (X-XO) perfused in rat pulmonary artery and the protection of vasoactive intestinal polypeptide (VIP) against the injury of pulmonary vascular permeability. After addition of xanthine oxidase in the perfusate reservoir containing xanthine, 125I-albumin leak index (125I-ALI) was remarkably increased while peak airway pressure (Paw) showed no significant increase, and perfusion pressure of pulmonary artery (Ppa) and lung wet/dry weight ratio (W/D) were only slightly increased. Xanthine plus xanthine oxidase also increased thromboxane B2 (TX B2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) in the perfusate. Treatment with VIP obviously reduced or totally prevented all signs of injury. Simultaneously, VIP also diminished or abolished the associated generation of arachidonate products. The results indicated that VIP has potent protective activity against injury of pulmonary vascular permeability and may be a physiological modulator of inflammatory damage to vascular endothelium associated with toxic oxygen metabolites.
authors.affiliation: PUMC Hospital, CAMS, Beijing.
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Sun
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002199:Capillary Permeability / Q000187:drug effects*; D008168:Lung / Q000098:blood supply*; D008297:Male; D011654:Pulmonary Edema / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013929:Thromboxane B2 / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000627:therapeutic use*; D014969:Xanthine Oxidase; D014970:Xanthines
chemical_list: D000975:Antioxidants; D014970:Xanthines; D014660:Vasoactive Intestinal Peptide; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D014969:Xanthine Oxidase